As expected, the European Commission
approves Alnylam Pharmaceuticals’ (NASDAQ:
ALNY) Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP) in adults and adolescents at least 12 years old.
A little over a month ago, the advisory group CHMP adopted a
positive opinion recommending approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.